PATENT CLAIM ANALYSIS

Application Number: 16271686
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "134100"]

Abstract:
The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Claim (Index 16):
A method of reducing the severity of a bleeding episode, comprising intravenously administering to a human hemophilia B subject in need thereof multiple doses of about 25 IU/kg to about 50 IU/kg of a chimeric Factor IX (\u201cFIX\u201d) polypeptide comprising human FIX having an amino acid sequence identical to amino acids 1 to 415 of SEQ ID NO:2 and an FcRn binding partner (\u201cFcRn BP\u201d) at a dosing interval of about 7 days between two doses, wherein the FcRn BP is human Fc or human albumin.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 99.0
- Lexical Diversity: 2.13636
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16271689', '15043457', '14982934', '15890284', '13809276']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8048899388757851
- 35 USC 102 Novelty (BERT): 0.7479179368952558
- Combined Prediction Score: 0.7991927386777322
- Mean Citation Score: 899.5850400000003
- Max Citation Score: 908.7646
- Similarity Product: 852.3388828147293

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test